Breast cancer (BC) is a frequently diagnosed cancer in women worldwide and imposes a significant burden on healthcare systems. Although chemotherapy remains a primary treatment modality, its efficacy is often compromised by multidrug resistance (MDR), leading to poor clinical outcomes and treatment failure. Multidrug resistance in BC arises through multiple mechanisms, including decreased apoptotic activity, overexpression of ATP-binding cassette (ABC) transporters, alterations in the tumor microenvironment, enhanced DNA repair capacity, and epithelial–mesenchymal transition. Conventional chemotherapeutic agents such as doxorubicin and paclitaxel are effective against BC cells; however, their clinical utility is limited by MDR, severe side effects including cardiotoxicity and neuropathy, and reduced efficacy in resistant tumors. To address these challenges, natural products interfere with resistance mechanisms through diverse pathways, inhibiting efflux pumps such as P-glycoprotein, restoring apoptosis, and modulating signal transduction pathways, including PI3K/Akt and NF- B. Furthermore, they induce autophagy, inhibit unregulated cell growth, and modify the tumor microenvironment to enhance therapeutic response. Compounds such as curcumin, silybin, apigenin, berberine, matrine, and -elemene have been shown to improve the effectiveness of chemotherapy, whether used as monotherapies or in combination with conventional drugs, while exhibiting minimal side effects compared to synthetic medicines. In conclusion, secondary metabolites derived from plants possess significant potential to overcome MDR in breast cancer. Their ability to attack resistance-related mechanisms through multiple pathways not only enhances the effectiveness of current therapy but also offers a promising source of safer and more effective anticancer agents.